NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

心因性暴食症治療市場 - 市場規模,佔有率,預測,機會分析:2020年∼2027年

Bulimia Nervosa Treatment Market, by Treatment Type (Drug Treatment and Non-drug Treatment ), by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版商 Coherent Market Insights 商品編碼 980007
出版日期 內容資訊 英文 156 Pages
商品交期: 2-3個工作天內
價格
心因性暴食症治療市場 - 市場規模,佔有率,預測,機會分析:2020年∼2027年 Bulimia Nervosa Treatment Market, by Treatment Type (Drug Treatment and Non-drug Treatment ), by Route of Administration, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
出版日期: 2020年12月23日內容資訊: 英文 156 Pages
簡介

心因性暴食症,有可能引起蛀牙,牙齦的衰弱,心臟的問題,自傷行為,脫水症,消化器官系統的問題等,威脅生命的各種併發症。

本報告提供全球心因性暴食症治療市場相關調查分析,市場概要,市場規模與預測,各市場區隔的市場分析,各地區的市場分析,競爭情形等相關的系統性資訊。

目錄

第1章 調查目的與前提條件

第2章 市場概要

第3章 市場動態、規定、趨勢分析

  • 市場動態
    • 促進因素
    • 阻礙因素
    • 市場機會
  • 影響分析
  • 流行病學
  • 主要的發展
  • 法規方案
  • PEST分析
  • 產品銷售
  • M&A方案

第4章 全球心因性暴食症治療市場:COVID-19大流行

  • COVID-19中的市場情形
  • 供給方面分析、需求面分析
  • COVID-19對憂鬱症、飲食障礙的影響
  • 為了對抗COVID-19的政府舉措

第5章 全球心因性暴食症治療市場:治療的各類型

  • 簡介
  • 藥物治療
  • 選擇性血清素回收抑制劑(SSRI)
  • 正腎上腺素再回收抑制劑(SNRI)
  • 苯重氮基鹽
  • 三環抗憂鬱藥物
  • 其他
  • 非藥物治療
  • 營養療法
  • 行動療法
  • 其他

第6章 全球心因性暴食症治療市場:各給藥途徑

  • 簡介
  • 口服
  • 靜脈內
  • 其他

第7章 全球心因性暴食症治療市場:各流通管道

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第8章 全球心因性暴食症治療市場:各地區

  • 簡介
  • 北美
  • 南美
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第9章 競爭情形

  • 企業簡介
    • Allergan, Inc.
    • Eli Lilly and Company
    • AstraZeneca plc
    • Alembic Pharmaceuticals Ltd
    • Bristol-Myers Squibb Company
    • GlaxoSmithKline plc
    • Pfizer Inc.
    • Johnson & Johnson Services, Inc.
    • Dr. Reddy's Laboratories Limited
    • Lupin Pharmaceuticals, Inc.
    • Aurobindo Pharma
    • Zydus Cadila
    • Apotex Inc.
    • Teva Pharmaceutical Industries Ltd
    • Sun Pharmaceutical Industries Ltd
  • 分析師的見解

第10章 Section

目錄

Title:
Bulimia Nervosa Treatment Market, by Treatment Type (Drug Treatment (Selective Serotonin Reuptake Inhibitor, Serotonin-Norepinephrine Reuptake Inhibitor, Benzodiazepines, Tricyclic Antidepressants, and Others) and Non-drug Treatment (Nutritional Therapy, Behavioral Therapy, and Others)), by Route of Administration (Oral, Intravenous, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Bulimia nervosa is a type of eating disorder, in which the person eat large amount of food (binge eating) within a short period of time, after which the person tends to lose weight by two ways: purging and non-purging. Purging includes vomiting post eating and non-purging includes fasting, enemas, use of laxatives and diuretics, and excessive exercising. Bulimia nervosa may lead to various life-threatening complications such as tooth & gum decay, heart problems, self-injury, dehydration, and digestive problems.

Market Dynamics

Research institutes are indulged in launching websites, in order to spread awareness about the latest eating disorders treatment options, among the population, which is expected to fuel growth of the market over the forecast period. For instance, in 2018, ECRI institute, a non-profit organization, launched a bulimia nervosa guide website for the patients and their caretakers. This website provide guidelines and latest information about the treatment options for the bulimia nervosa.

Research institutes are indulged in conducting clinical trials for finding the effectiveness of behavioral therapy for the treatment of eating disorders. For instance, on 7th November 2020, National Institute of Mental Health (NIMH) announced that, they are recruiting adult women patients suffering from bulimia nervosa for conducting clinical trials, in order to determine the effectiveness of cognitive behavioral therapy in the treatment of bulimia nervosa.

Key features of the study:

  • This report provides an in-depth analysis of global bulimia nervosa treatment market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2020-2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
  • It profiles leading players in the global bulimia nervosa treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
  • Key companies covered as a part of this study include Allergan, Inc., Eli Lilly and Company, AstraZeneca plc, Alembic Pharmaceuticals Ltd, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Pfizer Inc., Johnson & Johnson Services, Inc., Dr. Reddy's Laboratories Limited, Lupin Pharmaceuticals, Inc., Aurobindo Pharma, Zydus Cadila, Apotex Inc., Teva Pharmaceutical Industries Ltd, and Sun Pharmaceutical Industries Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
  • The global bulimia nervosa treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision making through various strategy matrices used in analyzing the bulimia nervosa treatment market

Detailed Segmentation:

  • Global Bulimia Nervosa Treatment Market, By Treatment Type:
    • Drug Treatment
  • Selective Serotonin Reuptake Inhibitor (SSRI)
  • Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
  • Benzodiazepines
  • Tricyclic Antidepressants
  • Others
    • Non-drug Treatment
  • Nutritional Therapy
  • Behavioral Therapy
  • Others
  • Global Bulimia Nervosa Treatment Market, By Route of Administration:
    • Oral
    • Intravenous
    • Others
  • Global Bulimia Nervosa Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Bulimia Nervosa Treatment Market, By Region:
    • North America
  • By Country
    • U.S.
    • Canada
  • By Treatment Type:
    • Drug Treatment
      • Selective Serotonin Reuptake Inhibitor (SSRI)
      • Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
      • Benzodiazepines
      • Tricyclic Antidepressants
      • Others
    • Non-Drug Treatment
      • Nutritional Therapy
      • Behavioral Therapy
      • Others
  • By Route of Administration
    • Oral
    • Intravenous
    • Others
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Latin America
  • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • By Treatment Type:
    • Drug Treatment
      • Selective Serotonin Reuptake Inhibitor (SSRI)
      • Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
      • Benzodiazepines
      • Tricyclic Antidepressants
      • Others
    • Non-Drug Treatment
      • Nutritional Therapy
      • Behavioral Therapy
      • Others
  • By Route of Administration
    • Oral
    • Intravenous
    • Others
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Europe
  • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
  • By Treatment Type:
    • Drug Treatment
      • Selective Serotonin Reuptake Inhibitor (SSRI)
      • Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
      • Benzodiazepines
      • Tricyclic Antidepressants
      • Others
    • Non-Drug Treatment
      • Nutritional Therapy
      • Behavioral Therapy
      • Others
  • By Route of Administration
    • Oral
    • Intravenous
    • Others
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Asia Pacific
  • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
  • By Treatment Type:
    • Drug Treatment
      • Selective Serotonin Reuptake Inhibitor (SSRI)
      • Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
      • Benzodiazepines
      • Tricyclic Antidepressants
      • Others
    • Non-Drug Treatment
      • Nutritional Therapy
      • Behavioral Therapy
      • Others
  • By Route of Administration
    • Oral
    • Intravenous
    • Others
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Middle East
  • By Country:
    • GCC
    • Israel
    • Rest of Middle East
  • By Treatment Type:
    • Drug Treatment
      • Selective Serotonin Reuptake Inhibitor (SSRI)
      • Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
      • Benzodiazepines
      • Tricyclic Antidepressants
      • Others
    • Non-Drug Treatment
      • Nutritional Therapy
      • Behavioral Therapy
      • Others
  • By Route of Administration
    • Oral
    • Intravenous
    • Others
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Africa
  • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
  • By Treatment Type:
    • Drug Treatment
      • Selective Serotonin Reuptake Inhibitor (SSRI)
      • Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
      • Benzodiazepines
      • Tricyclic Antidepressants
      • Others
    • Non-Drug Treatment
      • Nutritional Therapy
      • Behavioral Therapy
      • Others
  • By Route of Administration
    • Oral
    • Intravenous
    • Others
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Company Profiles
  • Allergan, Inc.*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Eli Lilly and Company
  • AstraZeneca plc
  • Alembic Pharmaceuticals Ltd
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • Dr. Reddy's Laboratories Limited
  • Lupin Pharmaceuticals, Inc.
  • Aurobindo Pharma
  • Zydus Cadila
  • Apotex Inc.
  • Teva Pharmaceutical Industries Ltd
  • Sun Pharmaceutical Industries Ltd

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Treatment Type
    • Market Snippet, By Route of Administration
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Epidemiology
  • Key Developments
  • Regulatory Scenario
  • PEST Analysis
  • Product launches
  • Acquisition and Merger Scenario

4. Global Bulimia Nervosa Treatment Market - Impact of Coronavirus (Covid - 19) Pandemic

  • During COVID-19 Market Situation
  • Supply Side and Demand Side Analysis
  • Impact of COVID-19 on Depression and Eating Disorders
  • Government Initiatives to Combat COVID-19

5. Global Bulimia Nervosa Treatment Market, By Treatment Type , 2016 - 2027 (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Drug Treatment
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Selective Serotonin Reuptake Inhibitor (SSRI)
  • Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
  • Benzodiazepines
  • Tricyclic Antidepressants
  • Others
  • Non-drug Treatment
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Nutritional Therapy
  • Behavioral Therapy
  • Others

6. Global Bulimia Nervosa Treatment Market, By Route of Administration, 2016 - 2027 (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Oral
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Intravenous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

7. Global Bulimia Nervosa Treatment Market, By Distribution Channel, 2016 - 2027 (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

8. Global Bulimia Nervosa Treatment Market, By Region, 2016 - 2027 (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, For Regions, 2017 - 2027
    • Regional Trends
  • North America
    • Market Size and Forecast, By Treatment Type , 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Treatment Type , 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Treatment Type , 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Treatment Type , 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Treatment Type , 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Country, 2016 - 2027 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Treatment Type , 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Route of Administration, 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027 (US$ Mn)
    • Market Size and Forecast, By Country/Region, 2016 - 2027 (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

9. Competitive Landscape

  • Company Profiles
    • Allergan, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • AstraZeneca plc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Alembic Pharmaceuticals Ltd
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Bristol-Myers Squibb Company
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • GlaxoSmithKline plc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Johnson & Johnson Services, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Dr. Reddy's Laboratories Limited
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Lupin Pharmaceuticals, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Aurobindo Pharma
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Zydus Cadila
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Apotex Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Teva Pharmaceutical Industries Ltd
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
    • Sun Pharmaceutical Industries Ltd
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Analyst Views

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact